Scaricare la presentazione
La presentazione è in caricamento. Aspetta per favore
1
Efficacy and safety of once-weekly bortezomib in multiple myeloma patients by Sara Bringhen, Alessandra Larocca, Davide Rossi, Maide Cavalli, Mariella Genuardi, Roberto Ria, Silvia Gentili, Francesca Patriarca, Chiara Nozzoli, Anna Levi, Tommasina Guglielmelli, Giulia Benevolo, Vincenzo Callea, Vincenzo Rizzo, Clotilde Cangialosi, Pellegrino Musto, Luca De Rosa, Anna Marina Liberati, Mariella Grasso, Antonietta P. Falcone, Andrea Evangelista, Michele Cavo, Gianluca Gaidano, Mario Boccadoro, and Antonio Palumbo Blood Volume 116(23):4745-4753 December 2, 2010 ©2010 by American Society of Hematology
2
Kaplan-Meier survival curves for patients who received once-weekly (gray line) or twice-weekly (black line) bortezomib (intention-to-treat population). Sara Bringhen et al. Blood 2010;116:4745-4753 ©2010 by American Society of Hematology
3
Cumulative incidence of sensory PN, accounting for competing events (death and any other PN type) in patients who received once-weekly or twice-weekly bortezomib. Sara Bringhen et al. Blood 2010;116:4745-4753 ©2010 by American Society of Hematology
Presentazioni simili
